Develops conditionally activated immune therapies for cancer and other immune-mediated conditions, including cytokine medicines and immune cell engagers for cancer.
10-K for FY2025, filed Mar 27, 2026We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system…View ↗
We are also utilizing this PREDATOR platform know-how and expertise to develop conditionally activated immune cell engagers. Immune cell…View ↗
Leveraging our PREDATOR platform and drug development capabilities, we are creating a portfolio of conditionally activated proinflammatory…View ↗
Jazz Pharmaceuticals Ireland Limited holds worldwide rights to develop and commercialize JZP898 under a collaboration and license agreement.
10-K for FY2025, filed Mar 27, 2026
8-K, filed Aug 21, 2026
On August 21, 2026, Werewolf Therapeutics, Inc., a Delaware corporation (“Werewolf”), entered into an Agreement and Plan of Merger (the…View ↗
8-K, filed Aug 20, 2026
On August 14, 2026 (the “Closing”), Werewolf Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase…View ↗
Added immune cell engagers
The latest report describes conditionally activated immune cell engagers alongside its INDUKINE cytokine medicines; the older report described its platform and pipeline mainly through INDUKINE molecules and other immune-oncology discovery programs.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 27, 2026
Competes with Anaveon, Anwita Biosciences, Ascendis Pharma, Asher Biotherapeutics, Aulos Bioscience, BioNTech, Cue Biopharma, DEKA Biosciences, Merck &, Medicenna Therapeutics, F. Hoffmann-La Roche, Synthekine, Xilio Therapeutics, Sanofi, DragonFly Therapeutics, Juno Therapeutics, OncoSec Medical, PDS Biotechnology, Philogen, and Sonnet BioTherapeutics
10-K for FY2025, filed Mar 27, 2026Our lead product candidate, WTX-124, if approved, may face competition from other IL-2 based cancer therapies. Proleukin (aldesleukin) has…View ↗
Loading...